Molecular Landscape of Metastatic Lung Adenocarcinoma in Bulgarian Patients—A Prospective Study
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26147017 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von George Dimitrov und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Medical University of Sofia, University Hospital "Tsaritsa Yoanna", 1527 Sofia, Bulgaria. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The support of the project BG16RFPR002-1.014-0002-С001 "CENTRE OF COMPETENCE IN PER-SONALIZED MEDICINE, 3D AND TELEMEDICINE, ROBOTIC ASSISTED AND MINIMALLY INV…, PRIDST 2021-2027.
Abstract (Originalsprache)
Lung adenocarcinoma exhibits a heterogeneous molecular landscape shaped by key oncogenic drivers and tumor suppressor gene alterations. Mutation frequencies vary geographically, influenced by genetic ancestry and environmental factors. However, the molecular profile of lung adenocarcinoma in Bulgarian patients remains largely uncharacterized. We conducted a prospective study of 147 Bulgarian patients with metastatic lung adenocarcinoma, analyzing clinicopathologic features and somatic mutation frequencies using next-generation sequencing. Key mutations and their prevalence were assessed and compared with published data from other populations. The cohort included predominantly male patients (68.0%) with a median age of 67 years. TP53 mutations were most frequent (41.5%), followed by EGFR alterations (19.0%) and KRAS c.34G>T (p.Gly12Cys) (17.0%). Over half of the patients (51.0%) harbored two or more gene mutations. Mutation frequencies aligned closely with European cohorts, exhibiting a lower prevalence of EGFR mutations compared to East Asian populations. This study characterizes the molecular landscape of lung adenocarcinoma in Bulgaria, highlighting the predominance of TP53 and KRAS mutations. The findings emphasize the need for comprehensive molecular profiling to inform targeted therapies and support precision oncology approaches tailored to the Bulgarian population. Further research is needed to validate these results and improve clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Medical University of Sofia, University Hospital "Tsaritsa Yoanna", 1527 Sofia, Bulgaria.
- Centre of Competence in Personalized Medicine, 3D and Telemedicine, Robotic Assisted and Minimally Invasive Surgery-Leonardo da Vinci, 5800 Pleven, Bulgaria.
- Department of Anatomy, Histology, Cytology and Biology, Medical University of Pleven, 5800 Pleven, Bulgaria.
- Medical Oncology Clinic, Heart and Brain Hospital, 5804 Pleven, Bulgaria.
- Department of Medical Genetics, Medical University of Pleven, 5800 Pleven, Bulgaria.
- Department of Clinical Pathology, Medical University of Pleven, 5800 Pleven, Bulgaria.
ORCID-Profile: George Dimitrov
Förderung
- The support of the project BG16RFPR002-1.014-0002-С001 "CENTRE OF COMPETENCE IN PER-SONALIZED MEDICINE, 3D AND TELEMEDICINE, ROBOTIC ASSISTED AND MINIMALLY INV…
- PRIDST 2021-2027
Zitieren
APA
Dimitrov, G., Nankov, V., Chilingirova, N., Kamburova, Z., & Popovska, S. (2025). Molecular Landscape of Metastatic Lung Adenocarcinoma in Bulgarian Patients—A Prospective Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26147017
Vancouver
Dimitrov G, Nankov V, Chilingirova N, Kamburova Z, Popovska S. Molecular Landscape of Metastatic Lung Adenocarcinoma in Bulgarian Patients—A Prospective Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26147017
BibTeX
@article{Dimitrov2025,
author = {Dimitrov, George and Nankov, Vladislav and Chilingirova, Natalia and Kamburova, Zornitsa and Popovska, Savelina},
title = {Molecular Landscape of Metastatic Lung Adenocarcinoma in Bulgarian Patients—A Prospective Study},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26147017}
}
EUVIMED